Is there enough evidence for routine use of drug-eluting stents in acute myocardial infarction with ST segment elevation?

Milorad Tešić; Goran Stanković

doi:10.2298/3598

Milorad Tešić Department of Diagnostics and Catheterization Laboratories, Clinic for Cardiology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Goran Stanković Department of Diagnostics and Catheterization Laboratories, Clinic for Cardiology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

DOI: https://doi.org/10.2298/3598

Keywords: myocardial infarction, acute disease, drug-eluting stents, stents, thrombosis, treatment outcome,

References

Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarc-tion: a quantitative review of 23 randomised trials. Lancet 2003; 361(9351): 13−20.

Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambarto-lomei A, et al. Coronary angioplasty with or without stent im-plantation for acute myocardial infarction. Stent Primary An-gioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341(26): 1949−56.

Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346(13): 957−66.

Morice M, Serruys PW, Sousa EJ, Fajadet J, Ban HE, Perin M, Falo-tico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773−80.

Stone GW, Ellis SG, Cannon L, Mann TJ, Greenberg JD, Spriggs D, et al.. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary ar-tery disease: a randomized controlled trial. JAMA 2005; 294(10): 1215−23.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis af-ter successful implantation of drug-eluting stents. JAMA 2005; 293(17): 2126−30.

Ong AT, Hoye A, Aoki J, Mieghem CA, Rodriguez GG, Sonnenschein K, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45(6): 947−53.

Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed Arterial Healing and Increased Late Stent Throm-bosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study. Cir-culation 2008; 118(11): 1138−45.

Sianos G, Papafaklis MI, Daemen J, Vaina S, Mieghem CA, Domburg RT, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial in-farction: the importance of thrombus burden. J Am Coll Car-diol 2007; 50(7): 573−83.

Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48(1): 193−202.

Camenzind E, Steg PG, Wijns W. Stent thrombosis late after im-plantation of first-generation drug-eluting stents: A Cause for Concern. Circulation 2007; 115(11): 1440−55.

Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297(18): 2001−9.

Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293(17): 2109−17.

Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Co-langelo S, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299(15): 1788−99.

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355(11): 1093−104.

Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 2011; 4(1): 14−23.

Laarman GJ, Suttorp MJ, Dirksen MT, Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355(11): 1105−13.

Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011; 4(1): 24−9.

Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong CS, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360(19): 1946−59.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, e al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HO-RIZONS-AMI): final 3-year results from a multicentre, ran-domised controlled trial. Lancet 2011; 377(9784): 2193−204.

Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, et al. Inci-dence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in pa-tients with acute myocardial infarction: an intravascular ultra-sound substudy of the Harmonizing Outcomes with Revascu-larization and Stents in Acute Myocardial Infarction (HORI-ZONS-AMI) trial. Circulation 2010; 122(11): 1077−84.

Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 2011; 123(3): 274−81.

Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgi-migli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33(8): 977−87.

Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implan-tation: a randomised, multicentre, open-label, controlled trial. Lancet 2012; 380(9851): 1396−405.

Palmerini T, Biondi-Zoccai G, Riva DD, et al. . Stent throm-bosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379(9824): 1393−402.

Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEAD-ERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378(9807): 1940−8.

Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Kløvgaard L, Kaltoft A, et al.Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008;118(11): 1155−62.

Kaltoft A, Kelbaek H, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010; 56(8): 641−5.

Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EX-AMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380(9852): 1482−90.

Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, et al. Stent thrombosis with everolimus-eluting stents: me-ta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5(3): 357−64.

Sudhir K, Hermiller JB, Naidu SS, Henry TD, Mao VW, Zhao W, et al. Clinical outcomes in real-world patients with acute myo-cardial infarction receiving XIENCE V((R)) everolimus-eluting stents: One-year results from the XIENCE V USA study. Ca-theter Cardiovasc Interv 2012; doi: 10.1002/ccd.24749 (In press)

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coro-nary artery disease. N Engl J Med 2010; 362(18): 1663−74.

Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tüller D, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308(8): 777−87.

Stefanini GG, Byrne RA, Serruys PW, Waha A, Meier B, Massberg S, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing per-cutaneous coronary intervention: a pooled analysis of individ-ual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33(10): 1214−22.

Piscione F, Piccolo R, Cassese S, Galasso G, De Rosa R, D'Andrea C, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percuta-neous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention 2010; 5(7): 853−60.

Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Val-gimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myo-cardial infarction. Eur Heart J 2007; 28(22): 2706−13.

Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009; 53(18): 1677−89.

Koppara T, Joner M, Bayer G, Steigerwald K, Diener T, Wittchow E. Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation. Thromb Haemost 2012; 107(6): 1161−71.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from rando-mized trials. Circulation 2012; 125(23): 2873−91.

Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a re-port from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33(5): 606−13.

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, et al. Randomized comparison of everolimus- and pacli-taxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2012; 58(1): 19−25.